Cancer Research · global
When Cancer Cells Change, How Should Treatment Be Chosen? Three Research Paths, from Resistance Mechanisms to Leukemia Transplantation
Prostate cancer researchers are attempting to restore treatment sensitivity in resistant tumors, while a small cell lung cancer team is developing a blood test to identify tumor characteristics. A separate U.S. national trial initiative aims to determine whether older patients with leukemia should undergo transplantation after remission.
The challenges of cancer treatment often arise at the next turning point: a tumor stops responding to drugs, cells change their characteristics, or a patient whose disease is in remission must choose between two treatments, each with its own costs. Research news compiled in September by Fred Hutch Cancer Center in the United States presents three paths of investigation at different stages—finding a molecular switch for prostate cancer resistance, developing a liquid biopsy for small cell lung cancer, and establishing comparative treatment evidence for older patients with acute myeloid leukemia.
The leukemia trial initiative announced on August 27 addresses clinical decision-making most directly. A team led by Mohamed Sorror plans to recruit approximately 800 patients at 18 U.S. medical centers and conduct three randomized trials comparing outcomes after remission between patients receiving hematopoietic stem cell transplantation and those continuing non-transplant treatment. The research focuses on older patients for whom both approaches are medically reasonable but sufficient comparative evidence is lacking.
Transplantation may provide longer-term disease control, but it also carries early toxicity and burdens on daily life. In addition to comparing survival, the trials will therefore track quality of life, physical and cognitive function, treatment toxicity, and hospitalization. The U.S. Patient-Centered Outcomes Research Institute (PCORI) plans to support the initiative with $15 million over five years. However, the announcement explicitly states that funding remains subject to completion of business and programmatic reviews and execution of a formal award agreement. This is a research initiative intended to generate evidence; no results are yet available to determine which strategy is better.
In prostate cancer, a study published on April 15 in the *Journal of Clinical Investigation* focused on cancer cells’ ability to change their differentiation state, known as “lineage plasticity.” The study found that the region of eIF4E that binds to and recognizes the messenger RNA cap structure can influence which cellular characteristics a tumor maintains. eIF4E is involved in the initiation of protein production. In experimental models, inhibiting this region shifted tumors resistant to androgen receptor blockade toward a luminal state and restored their sensitivity to treatment.
The finding suggests an approach to giving existing therapies another opportunity to work by changing how cancer cells produce proteins. Patient data also showed that, in castration-resistant prostate cancer, higher eIF4E expression was associated with more rapid development of resistance to androgen receptor pathway inhibitors. However, the patient data show an association; whether inhibiting eIF4E can safely reverse resistance in human tumors still requires validation in clinical research.
Another path begins with gaining a clearer view of how tumors change. David MacPherson and Gavin Ha received a $1.5 million grant from the Andy Hill CARE Fund to advance a cell-free DNA sequencing assay called SCLCpheno-seq. Tissue biopsies from small cell lung cancer sometimes provide insufficient material for in-depth analysis of molecular subtypes, so the team hopes to obtain genomic features and features reflecting transcriptional states from plasma samples. One intended use is to identify cases in which non-small cell lung cancer has transformed into small cell lung cancer.
Under the plan announced on August 13, the funding will support validation using clinical samples and analysis of the relationship between tumor biological characteristics and patient outcomes in a completed clinical trial. Whether the assay can accurately distinguish different states and thereby help guide treatment selection is the question the next stage aims to answer. From molecular mechanisms and blood testing to randomized trials, these three efforts address different gaps in treatment decision-making, and each requires validation appropriate to its intended use.